Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.

Autor: Lesuisse D; Rare and Neurologic Disease Research, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91935, France. Electronic address: dominique.lesuisse@sanofi.com., Malanda A; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France., Peyronel JF; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France., Evanno Y; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France., Lardenois P; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France., De-Peretti D; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France., Abécassis PY; DMPK, Sanofi, 13 quai Jules Guesde, Vitry-sur-Seine F-94403, France., Barnéoud P; Rare and Neurologic Disease Research, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91935, France., Brunel P; Preclinical Safety, Sanofi, 3, digue d' Alfortville, Alfortville F-94140, France., Burgevin MC; Translational Science, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France., Cegarra C; Rare and Neurologic Disease Research, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91935, France., Auger F; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France., Dommergue A; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France., Lafon C; CNS Department, Sanofi, 195 route d'Espagne, F-31036 Toulouse, France., Even L; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France., Tsi J; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France., Luc TPH; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France., Almario A; Medicinal Chemistry, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France., Olivier A; Translational Science, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France., Castel MN; CNS Department, 13, quai Jules Guesde, F-94403 Vitry-sur-Seine Cedex, France., Taupin V; Rare and Neurologic Disease Research, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91935, France., Rooney T; Rare and Neurologic Disease Research, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91935, France., Vigé X; Translational Science, Sanofi, 1 av Pierre Brossolette, Chilly Mazarin F-91385, France.

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2019 Apr 01; Vol. 29 (7), pp. 929-932. Date of Electronic Publication: 2019 Jan 30.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Synthesis of aminopyridines and aminopyridones by cobalt-catalyzed [2+2+2] cycloadditions involving yne-ynamides: scope, limitations, and mechanistic insights.

Autor: Garcia P; UPMC, Univ Paris 06, IPCM 7201, 4 Place Jussieu, 75252 Paris Cedex 05, France., Evanno Y, George P, Sevrin M, Ricci G, Malacria M, Aubert C, Gandon V

Publikováno v: Chemistry (Weinheim an der Bergstrasse, Germany) [Chemistry] 2012 Apr 02; Vol. 18 (14), pp. 4337-44. Date of Electronic Publication: 2012 Mar 01.

Synthetic strategies of pyridazino[4,5-b]indoles.

Autor: Farghaly, Abdel-Rahman A. H.¹ farghaly431@gmail.com

Publikováno v: ARKIVOC: Online Journal of Organic Chemistry. 2023, Vol. 2023, p1-31. 31p.

Synthesis and Evaluation of Photophysical Properties of C‐3 Halogenated Derivatives of 2‐Phenylimidazo[1,2‐a]pyridine.

Autor: Chen, Hong¹, Wang, Yanyan¹, Liu, Qingjie¹, Guo, Yanchun¹ ycguo@zzu.edu.cn, Cao, Shuxia¹ csx@zzu.edu.cn, Zhao, Yufen^1,2

Publikováno v: Chinese Journal of Chemistry. Oct2022, Vol. 40 Issue 19, p2313-2328. 16p.